Podrobný výpis o publikaci

PLEVA, Leos, Pavel KUKLA a Ota HLINOMAZ. Treatment of coronary in-stent restenosis: a systematic review. Journal of Geriatric Cardiology. Beijing: Science Press, 2018, roč. 15, č. 2, s. 173-184. ISSN 1671-5411. Dostupné z: https://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007.

Další formáty: BibTeX LaTeX RIS

Základní údaje
Originální název	Treatment of coronary in-stent restenosis: a systematic review
Autoři	PLEVA, Leos (203 Česká republika, garant), Pavel KUKLA (203 Česká republika) a Ota HLINOMAZ (203 Česká republika, domácí).
Vydání	Journal of Geriatric Cardiology, Beijing, Science Press, 2018, 1671-5411.

Další údaje
Originální jazyk	angličtina
Typ výsledku	Článek v odborném periodiku
Obor	30201 Cardiac and Cardiovascular systems
Stát vydavatele	Čína
Utajení	není předmětem státního či obchodního tajemství
Impakt faktor	Impact factor: 1.763
Kód RIV	RIV/00216224:14110/18:00104044
Organizační jednotka	Lékařská fakulta
Doi	http://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007
UT WoS	000429624200007
Klíčová slova anglicky	Drug-eluting balloon; Drug-eluting stent; In-stent restenosis
Štítky	14110115, rivok
Příznaky	Mezinárodní význam, Recenzováno
Změnil	Změnila: Soňa Böhmová, učo 232884. Změněno: 11. 2. 2019 15:38.

Anotace
Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.

Anotace

Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.